In the first five years of operations, EATRIS has shown strong proof of concept of the value of the services portfolio, with users ranging from academia, SMEs, large pharma, to biotech and research funding organisations. The overarching aim of EATRIS-Plus is to support the long-term sustainability (LTS) of EATRIS by delivering innovative scientific tools to the research community, strengthening the infrastructure’s financial model and reinforcing EATRIS leadership in the European Research Area (ERA), particularly in the field of Personalised Medicine (PM) research and development.
The project comprises 19 partners including all current national nodes of the research infrastructure, academic representatives of new prospective member countries as well as umbrella organisations representing the patients’ voice and biotech companies EATG’s role in the project Is to coordinate the Patients Advisory Committee (PAC).
The omic tools will be developed and tested with a real-setting demonstrator, an already established cohort of 1,000 healthy individuals in Czechia upon whom genomic sequencing has been already performed. Information available on this healthy individual cohort will be augmented during the project with transcriptomic, proteomic and metabolomic data.
By providing such toolbox to the research community, EATRIS-Plus will be the engine to enable high-quality research in the context of patient stratification and accelerate the implementation of Personalised Medicine solutions. EATRIS is the European Infrastructure for Translational Medicine providing services for accelerating biomedical innovation.
The main goals of the EATRIS-Plus will be to:
|EATG contact person(s):||Karina Huberman – email@example.com|
|Duration of the project/initiative:||48 months (started in January 2020)|
|Project/initiative Main Partner(s):||19 partners including all current national nodes of the research infrastructure, academic representatives of new prospective member countries as well as umbrella organisations representing the patients’ voice and biotech companies|
|Main Funding Sources:||IMI|
|Communication Disclaimer:||This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 871096.|
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.